Adding utidelone to capecitabine after surgery for triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests whether adding utidelone (an investigational drug) to capecitabine (a standard chemo pill) after surgery can reduce the chance of breast cancer returning in patients with triple-negative breast cancer who still had cancer cells after neoadjuvant chemotherapy. Participation could help improve your treatment plan to lower the risk of recurrence.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 70 years old.
- You were diagnosed with triple-negative breast cancer and had surgery to remove the tumor.
- You received at least 4 cycles of chemotherapy before surgery, but cancer cells were still present after surgery (no complete response).
- You have not had any other cancer treatment after surgery, except possibly radiation therapy.
- Your cancer has not spread to distant organs.
- You have not previously taken capecitabine or utidelone.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new chemotherapy drug called utidelone, given before surgery for early high-risk or locally advanced breast cancer. The goal is to see if this drug can shrink tumors and improve outcomes. It may be a treatment option for people who meet the specific criteria.
This trial tests a combination of two drugs, utidelone and cisplatin, given before surgery to shrink breast tumors. The goal is to make surgery more effective and improve outcomes.
This trial tests whether a chemotherapy pill called capecitabine can help people with low-risk triple negative breast cancer after surgery. It is for patients with stage I disease who have certain features that suggest a lower chance of recurrence.
This Phase 3 study tests whether adding capecitabine (a chemotherapy pill) after breast cancer surgery can lower the chance the cancer comes back. It targets people with hormone-receptor–positive and HER2-negative breast cancer who are considered “high risk.”
This trial uses a blood test called ctDNA to see who is at higher risk after surgery and standard chemotherapy for triple-negative breast cancer. If your ctDNA test is positive, you may receive an extra “boost” treatment to help reduce the chance the cancer returns.
This trial looks at whether adding a chemotherapy medicine called capecitabine (taken in smaller, regular doses) to the standard after-surgery (adjuvant) treatment can lower the chance of cancer coming back in people with early-stage, high-risk HER2-positive breast cancer. It targets patients who still had cancer left after earlier treatment or who had higher-risk tumor features.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.